Dustin Samples

Cancer Nursing Today nonprod

One of the most severe complications after organ transplant is post-transplant lymphoproliferative disorder (PTLD). This condition occurs due to the use of immunosuppressants during and after transplant surgery. It is characterized by an uncontrolled proliferation of B cell lymphocytes, causing the development of lesions, which can become malignant if the B cells undergo mutations. Symptoms can resemble infectious mononucleosis, including fatigue, weight loss, fever, night sweats, and pain related to developing tumors.Treatment for PTLD generally involves the reduction of immunosuppressing agents and may include rituximab. However, a reduction in immunosuppression can lead to transplant rejection, graft-versus-host disease, cancer relapse, or other diseases. As such, the optimal treatment remains unknown.In a case series published in The Journal of Pediatric Hematology/Oncology, clinicians from the Mayo Clinic in Rochester, Minnesota, presented 3 pediatric patients with plasmacytic PTLD.Per the article, &ldquo;Two patients received a standard rituximab-based approach and relapsed, prompting additional chemotherapy.&rdquo; However, their third patient received the novel combination of bortezomib, dexamethasone, and daratumumab. &ldquo;This regimen was safe, well-tolerated, and resulted in a 2-year remission,&rdquo; reported the clinicians.Given this is a single case, extreme caution must be given when interpreting the results. However, larger, sufficiently powered studies should be undertaken to determine the efficacy of this therapeutic trio in the pediatric immunosuppressed transplant patient population with some scientific certainty.<h3>Reference</h3><a href="https://journals.lww.com/jpho-online/Abstract/9900/An_Effective_Combination_Therapy_for_the_Treatment.179.aspx" target="_blank" rel="noopener">An Effective Combination Therapy for the Treatment of Pediatric Monomorphic Post-transplant Lymphoproliferative Disorder With Plasmacytic Differentiation</a>.

Novel Trio of Bortezomib, Dexamethasone, and Daratumumab in Pediatric Plasmacytic PTLD Treatment

Lymphoma

A case series demonstrated the effectiveness of a novel trio for pediatric plasmacytic PTLD.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe